Literature DB >> 30559614

Clinical Observations, Plasma Retinol Concentrations, and In Vitro Lymphocyte Functions in Children With Sickle Cell Disease.

Solo R Kuvibidila1, Renée Gardner1, Maria Velez1, Raj Warrier1,1,2.   

Abstract

BACKGROUND: Children with sickle cell disease (SCD) often have infections, growth deficits, and impaired immunity, problems that also are observed in individuals with a vitamin A deficiency (plasma retinol concentration <20 μg/dL). The goal of this study was to investigate the association between vitamin A, health status, and the in vitro immune function of children with SCD.
METHODS: Fifty-nine children (40 SS, 11 SC, and 8 Sβthalassemia [Sβthal] hemoglobin genotypes) 9 months to 18 years old were investigated for plasma levels of retinol, retinol binding protein, C-reactive protein, alpha-1-acid glycoprotein, lymphocyte proliferation, and interleukin (IL)-2 activity in supernatant of phytohemagglutinin-treated lymphocytes.
RESULTS: The plasma retinol concentrations of children with SCD (mean 57.6 μg/dL, range 4.6-116 μg/dL) were not different from those of 21 normal individuals (mean 62 μg/dL, range 28.7-162 μg/dL). Plasma retinol concentrations did not vary by hemoglobin genotype but were lower in boys than in girls (P < 0.05) and were also lower in children with inflammation (P = 0.1). Seven children (11.9%) (6 HbSS, 1 HbSβ0thal) were vitamin A-deficient, and 9 children (15.3%) had suboptimal vitamin A status (plasma retinol concentration of 20-29 μg/dL). Children with vitamin A deficiency had slightly lower height (P = 0.09) and weight mean percentiles, lymphocyte proliferative responses, and IL-2 activity (P > 0.1), but higher means of C-reactive protein (P = 0.05), pain crisis episodes and inflammation (P = 0.1), and health scores (P > 0.1) than children who were not vitamin A-deficient. Lymphocyte proliferative responses negatively correlated with health score, pain crisis episodes, and blood units received, but positively correlated with retinol binding protein (P < 0.05 to P = 0.1).
CONCLUSION: Identification and correction of suboptimal vitamin A status in children with SCD may improve immunity and attenuate certain health complications associated with this disease.

Entities:  

Keywords:  Anemia–sickle cell; infection; inflammation; interleukin-2; lymphocyte proliferation; vitamin A

Year:  2018        PMID: 30559614      PMCID: PMC6292479          DOI: 10.31486/toj.17.0044

Source DB:  PubMed          Journal:  Ochsner J        ISSN: 1524-5012


  35 in total

1.  Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations.

Authors:  J A Hank; J Surfus; J Gan; M Albertini; M Lindstrom; J H Schiller; K M Hotton; M Khorsand; P M Sondel
Journal:  Clin Cancer Res       Date:  1999-02       Impact factor: 12.531

Review 2.  NFAT proteins: key regulators of T-cell development and function.

Authors:  Fernando Macian
Journal:  Nat Rev Immunol       Date:  2005-06       Impact factor: 53.106

3.  Effect of zinc supplementation on growth and body composition in children with sickle cell disease.

Authors:  Babette S Zemel; Deborah A Kawchak; Ellen B Fung; Kwaku Ohene-Frempong; Virginia A Stallings
Journal:  Am J Clin Nutr       Date:  2002-02       Impact factor: 7.045

4.  Serum retinol distributions in residents of the United States: third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  C Ballew; B A Bowman; A L Sowell; C Gillespie
Journal:  Am J Clin Nutr       Date:  2001-03       Impact factor: 7.045

5.  Retinol binding protein as a surrogate measure for serum retinol: studies in vitamin A-deficient children from the Republic of the Marshall Islands.

Authors:  M V Gamble; R Ramakrishnan; N A Palafox; K Briand; L Berglund; W S Blaner
Journal:  Am J Clin Nutr       Date:  2001-03       Impact factor: 7.045

6.  Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD).

Authors:  A S Prasad; F W Beck; J Kaplan; P H Chandrasekar; J Ortega; J T Fitzgerald; P Swerdlow
Journal:  Am J Hematol       Date:  1999-07       Impact factor: 10.047

7.  Vitamin A levels and immunity in humans.

Authors:  Janine Jason; Lennox K Archibald; Okey C Nwanyanwu; Anne L Sowell; Ian Buchanan; Joshua Larned; Michael Bell; Peter N Kazembe; Hamish Dobbie; William R Jarvis
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

8.  Retinoic acid stimulates the cell cycle machinery in normal T cells: involvement of retinoic acid receptor-mediated IL-2 secretion.

Authors:  Aase Ertesvag; Nikolai Engedal; Soheil Naderi; Heidi Kiil Blomhoff
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

9.  Survival of activated human T lymphocytes is promoted by retinoic acid via induction of IL-2.

Authors:  Nikolai Engedal; Aase Ertesvag; Heidi Kiil Blomhoff
Journal:  Int Immunol       Date:  2004-03       Impact factor: 4.823

10.  Vitamin A status, hospitalizations, and other outcomes in young children with sickle cell disease.

Authors:  Joan I Schall; Babette S Zemel; Deborah A Kawchak; Kwaku Ohene-Frempong; Virginia A Stallings
Journal:  J Pediatr       Date:  2004-07       Impact factor: 4.406

View more
  3 in total

1.  Hemoglobin alters vitamin carrier uptake and vitamin D metabolism in proximal tubule cells: implications for sickle cell disease.

Authors:  Megan L Gliozzi; Youssef Rbaibi; Kimberly R Long; Dario A Vitturi; Ora A Weisz
Journal:  Am J Physiol Cell Physiol       Date:  2019-09-11       Impact factor: 4.249

2.  In Vitro Lymphocyte Functions in Undernourished Children With Sickle Cell Anemia.

Authors:  Solo R Kuvibidila; Renée Gardner; Maria C Velez; Lolie Yu; Rajasekharan P Warrier
Journal:  Ochsner J       Date:  2020

Review 3.  What Are the Effects of Vitamin A Oral Supplementation in the Prevention and Management of Viral Infections? A Systematic Review of Randomized Clinical Trials.

Authors:  Alessandra Sinopoli; Susanna Caminada; Claudia Isonne; Maria Mercedes Santoro; Valentina Baccolini
Journal:  Nutrients       Date:  2022-10-01       Impact factor: 6.706

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.